Invitrogen and Applied Biosystems to Merge in $6.7 Billion Deal

The combined company will generate over 70% of its revenue from consumables and services. In addition, cost savings, operational and other efficiencies are expected to add to the bottom line.

Gregory T. Lucier, chairman and chief executive officer of Invitrogen, said, "With this acquisition, we are nearly doubling our consumables business as almost half of Applied Biosystems's revenues are consumable in nature. It also provides significant value creating opportunities for customers, shareholders and employees alike.”

Industry insiders commented that the transaction makes sense given the overlapping expertise, sales force, and product lines of both companies. Insiders also thought the price paid for Applied Biosystems to be somewhat of a bargain.

The new company will have considerable presence in key growth markets and advanced technical capabilities in the areas of genetics, proteomics, and cellular biology. Invitrogen and Applied Biosystems have highly recognizable brands in core structural and functional genomic product areas, cell biology, proteomics, as well as essential tools such as transfection reagents, antibodies, fluorescent technologies, and cell culture reagents.

Mark P. Stevenson, president and chief operating officer of Applied Biosystems, said, "Combining Applied Biosystems's and Invitrogen's capabilities will realize growth opportunities greater and faster than either company could achieve independently.”

Following the close of the transaction, the combined organization will be named Applied Biosystems, Inc. and will have its corporate headquarters in Carlsbad, CA, USA. The board of directors of the new company will be composed of the nine current Invitrogen board members and three additional members from the current Applera board. Gregory T. Lucier will be chairman and chief executive officer of the combined company, and Mark P. Stevenson will become president and chief operating officer.

The cash and stock transaction is expected to be split 45 and 55% respectively. Applera-Applied Biosystems shareholders will receive $38 dollars per share of common stock, an amount representing a 17% premium over market value. However, under the terms of the agreement the split and the total value per share may differ depending on certain market conditions.

The transaction is subject to approval by Invitrogen and Applera-Applied Biosystems shareholders, customary closing conditions and regulatory approvals. The transaction is expected to close sometime in the fall of 2008.

Invitrogen Corporation (Carlsbad, CA, USA) provides products and services that support academic, government research institutions, pharmaceutical, and biotech companies worldwide. The company employs about 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007.

Applera-Applied Biosystems (Foster City, CA, USA) serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Applied Biosystems employs about 5,000 worldwide and reported sales of approximately $2.1 billion during fiscal 2007.


Related Links:
Invitrogen Corporation
Applied Biosystems